Showing results (1-10 of 328) with videos related to
Sort By:
Pageof 33
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 27, 2006
The epidermal growth factor receptor pathway: a model for targeted therapyMaurizio Scaltriti, José BaselgaClinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 15, 2016
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to TherapyMaurizio Scaltriti, Moshe Elkabets, José BaselgaBreast Cancer Research : BCR|May 24, 2011
Synergy between trastuzumab and pertuzumab for human epidermal growth factor 2 (Her2) from colocalization: an in silico based mechanismGloria Fuentes, Maurizio Scaltriti, José Baselga, et al.Pharmacology & Therapeutics|December 10, 2015
AKT signaling in ERBB2-amplified breast cancerF Javier Carmona, Filippo Montemurro, Srinivasaraghavan Kannan, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 16, 2016
Differential Receptor Tyrosine Kinase PET Imaging for Therapeutic GuidanceEric Wehrenberg-Klee, N Selcan Turker, Pedram Heidari, et al.The EMBO Journal|June 24, 2006
Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translationJudit Anido, Maurizio Scaltriti, Joan Josep Bech Serra, et al.The Journal of Pathology|October 10, 2013
Biomarkers of drugs targeting HER-family signalling in cancerFilippo Montemurro, Maurizio ScaltritiCancer Discovery|December 6, 2011
mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signalingVanessa S Rodrik-Outmezguine, Sarat Chandarlapaty, Nen C Pagano, et al.Proceedings of the National Academy of Sciences of the United States of America|March 2, 2016
Pten loss promotes MAPK pathway dependency in HER2/neu breast carcinomasSaya H Ebbesen, Maurizio Scaltriti, Carl U Bialucha, et al.The Oncologist|February 1, 2011
Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancerJosé BaselgaPageof 33